目的 觀察阿加曲班注射液治療進展性腦梗死的臨床療效和安全性。方法 將100例進展性腦梗死患者隨機分為治療組（50例）和對照組（50例），兩組均給以活血化瘀、清除自由基、改善腦代謝、控制血壓和血糖等常規(guī)治療，均給予依達拉奉，30 mg/次，用100 mL生理鹽水稀釋，30 min內(nèi)滴完，2 次/d。治療組在此基礎上加用阿加曲班注射液，第1、2天每天用阿加曲班60 mg，以750 mL生理鹽水稀釋，24 h持續(xù)靜脈滴注；其后5 d每天用阿加曲班10 mg以100～250 mL生理鹽水稀釋，分早晚2次持續(xù)靜脈滴注，每次3 h。對照組使用低分子肝素鈣，4 100 U/次，每12小時腹部皮下注射一次，兩組均治療14 d。治療前后使用NIHSS評分比較兩組神經(jīng)功能障礙程度，Barthel指數(shù)評價康復情況，統(tǒng)計兩組臨床治療的總有效率，同時觀察兩組患者的不良反應。結(jié)果 兩組治療后14 d NIHSS評分均明顯低于治療前（P＜0.05）。治療后，治療組較對照組NIHSS評分有顯著改善（P＜0.05），治療組與對照組總有效率分別為98%、72%，兩組比較差異有統(tǒng)計學意義（P＜0.05）。兩組均無不良反應發(fā)生。結(jié)論 阿加曲班注射液對進展性腦梗死有較好的治療效果，且無不良反應發(fā)生。

Objective To evaluate the efficacy and safety of Argatroban Injection in the treatment of progressive cerebral infarction. Methods The patients (100 cases) diagnosed as progressive cerebral infarction were randomly divided into treatment (50 cases) and control (50 cases) groups. The two groups were given the treatment to improve blood circulation, remove free radicals, improve cerebral metabolism, and control blood pressure and sugar. They were iv administered with edaravone (30 mg) added into 100 mL physiological saline, and drop within 30 min, twice daily. In addition, the treatment group was treated with Argatroban Injection (60 mg diluted with 750 mL physiological saline) through 24 h continuous iv pump infusion on the first 2 d. The next 5 d they were treated with Argatroban Injection (10 mg diluted with 100—250 mL physiological saline), through continuous 3 h iv infusion twice daily in the morning and evening. The patients in the control group were treated with low molecular weight heparin, 4 100 U/time, and they were administered with abdominal sc injection every 12 h. Two groups were treated for 14 d. The degrees of neurological deficits were evaluated by NIHSS scoring and the rehabilitation was evaluated by Barthel index before and after the treatment. The efficiency and adverse reactions were observed. Results Within 14 d after the treatment, the NIHSS scores of the two groups were significantly lower than those before the treatment (P < 0.05) and the difference between the two groups was statistically significant (P < 0.05). The efficiency for the patients both in the treatment and control groups was 98% and 72% with the significant difference (P < 0.05). There was no adverse reaction in the two groups. Conclusion Argatroban Injection has a accurate curative effect on the progressive cerebral infarction, which has no adverse reaction.